The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease
JAMA · 2024
DOI: 10.1001/jama.2024.11703 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Edward R Scheffer Cliff und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hos…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy, Health Equity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the high cost of new gene therapies for sickle cell disease, the challenges these costs pose for health care access, and new policy approaches to ensure fair reimbursement for payers and manufacturers without further increasing health care costs or barriers to access for underserved populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Cliff, E. R. S., & Tessema, F. A. (2024). The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease. JAMA. https://doi.org/10.1001/jama.2024.11703
Vancouver
Cliff ERS, Tessema FA. The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease. JAMA. 2024. doi:10.1001/jama.2024.11703
BibTeX
@article{Cliff2024,
author = {Cliff, Edward R Scheffer and Tessema, Frazer A},
title = {The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.11703}
}
EUVIMED